Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism

Pediatric Nephrology

Volumn 14, Issue 7, 2000, Pages 641-645

  Salusky, Isidro B ^a,b   Goodman, William G ^a   Kuizon, Beatriz D ^a   Salusky, I B ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Adynamic bone; Calcitriol therapy; Parathyroid hormone; Peritoneal dialysis; Secondary hyperparathyroidism

Indexed keywords

CALCITRIOL; CALCIUM; PARATHYROID HORMONE;

ADOLESCENT; BONE GROWTH; CALCIUM BLOOD LEVEL; CARTILAGE CELL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; GROWTH RETARDATION; HUMAN; KIDNEY FAILURE; PARATHYROID HORMONE BLOOD LEVEL; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SCHOOL CHILD; SECONDARY HYPERPARATHYROIDISM;

EID: 0034130615     PISSN: 0931041X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s004670000352     Document Type: Conference Paper

References (33)

1. Stickler GB, Bergen BJ (1973) A review: short stature in renal disease. Pediatr Res 7:978-982
2. Fine RN (1992) Stimulating growth in uremic children. Kidney Int 42:188-197
3. Tönshoff B, Cronin MJ, Reichert M, Haffner D, Wingen A-M, Blum WF, Mehls O, The European Study Group for Nutritional Treatment of Chronic Renal failure in Childhood, and Members of the German Study Group for Growth Hormone Treatment in Chronic Renal Failure (1997) Reduced concentration of serum growth hormone (GH)-binding protein in children with chronic renal failure: correlation with GH insensitivity. J Clin Endocrinol Metab 82:1007-1013
4. Blum WF, Ranke M, Kietzmann K, Tönshoff B, Mehls O (1989) Excess of IGF-binding proteins in chronic renal failure: evidence for relative GH resistance and inhibition of somatomedin activity. In: Hintz RL et al (ed) Insulin-like growth factor binding proteins. Elsevier, Amsterdam, pp 93-101
5. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, Goodman WG (1988) Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int 33:975-982
6. Sherrard DJ, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A, Saiphoo C, Fenton SS, Segre GV (1993) The spectrum of bone disease in end-stage renal failure - an evolving disorder. Kidney Int 43:436-442
7. Torres A, Lorenzo V, Hernandez D, Rodriguez JC, Concepcion MT, Rodriguez AP, Hernandez A, De Bonis E, Darias E, Gonzales-Posada JM et al. (1995) Bone disease in predialysis, hemodialysis, and CAPD patients: evidence of a better bone response to PTH. Kidney Int 47:1434-1442
8. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160-1166
9. Salusky IB, Kuizon BD, Belin T, Ramirez JA, Gales B, Segre GV, Goodman WG (1998) Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration. Kidney Int 54:907-914
10. Hernandez D, Concepcion MT, Lorenzo V, Martinez ME, Rodriguez A, De Bonis E, Gonzalez-Posada JM, Felsenfeld AJ, Rodriguez M, Torres A (1994) Adynamic bone disease with negative aluminum staining in predialysis patients: prevalence and evolution after maintenance dialysis. Nephrol Dial Transplant 9:517-523
11. Salusky IB, Ramirez JA, Oppenheim WL, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253-258
12. 3 in childhood renal osteodystrophy. N Engl J Med 298:238-242
13. 3 on renal function, mineral balance, and growth in children with severe chronic renal failure. Pediatrics 68:559-571
14. Klaus G, Mehls O, Hinderer J, Ritz E (1991) Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 337:800-801
15. Slatopolsky E, Weerts C, Thielan J, Horst RL, Harter H, Martin KJ (1984) Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest 74:2136-2143
16. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, Lobaugh BA (1994) Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int 45:1710-1721
17. Cano F, Delucchi A, Wolff E, Rodriguez E, Fuentes A (1995) Calcitriol oral pulse therapy in children with renal osteodystrophy. Pediatr Nephrol 9:606-608
18. Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N, Slatopolsky E (1987) The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int 31:795-799
19. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during treatment with intermittent calcitriol and dialysis in children with chronic renal failure. Kidney Int 53:205-211
20. Chang W, Tu C, Chen TH, Komuves L, Oda Y, Pratt SA, Miller S, Shoback D (2000) Expression and signal transduction of calcium-sensing receptors in cartilage and bone. Endocrinology 140:5883-5893
21. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T (1999) Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293
22. Saggese G, Federico G, Cinquanta L (1993) In vitro effects of growth hormone and other hormones on chondrocytes and osteoblast-like cells. Acta Paediatr [Suppl] 391:54-59
23. Boyan BB, Schwartz Z, Carnes DL Jr, Ramirez V (1988) The effects of vitamin D metabolites on the plasma and matrix vesicle membranes of growth and resting cartilage cells in vitro. Endocrinology 122:2851-2860
24. Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Jüppner H, Goodman WG (1998) Growth of long bones in renal failure: roles of hyperparathyroidism, growth hormone and calcitriol. Kidney Int 54:1879-1887
25. Lanske B, Karaplis AC, Lee K, Luz A, Vortkamp A, Pirro A, Karperien M, Defize LHK, Ho C, Mulligan RC, Abou-Samra AB, Jüppner H, Segre GV, Kronenberg HM (1996) PTH/ PTHrP receptor in early development and Indian hedgehog-regulated bone growth. Science 273:663-666
26. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, Tabin CJ (1996) Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-related protein. Science 273: 613-622
27. Amizuka N, Warshawsky H, Henderson JE, Goltzman D, Karaplis AC (1994) Parathyroid hormone-related peptide-depleted mice show abnormal epiphyseal cartilage development and altered endochondral bone formation. J Cell Biol 126: 1611-1623
28. Lee K, Lanske B, Karaplis AC, Deeds JD, Kohno H, Nissenson RA, Kronenberg HM, Segre GV (1996) Parathyroid hormone-related peptide delays terminal differentiation of chondrocytes during endochondral bone development. Endocrinology 137: 5109-5118
29. Karaplis AC, Luz A, Glowacki J, Bronson RT, Tybulewicz VLJ, Kronenberg HM, Mulligan RC (1994) Lethal skeletal dysplasia from targeted disruption of the parathyroid hormone-related peptide gene. Genes Dev 8:277-289
30. Ureña P, Ferreira A, Morieux C, Drüeke T, de Vernejoul MC (1996) PTH/PTHrP receptor mRNA is downregulated in epiphyseal cartilage growth plate of uraemic rats. Nephrol Dial Transplant 11:2008-2016
31. Sanchez CP, Salusky IB, Kuizon BD, Abdella P, Jüppner H, Goodman WG (1998) Changes in growth plate morphology in a rat model of adynamic bone (abstract). J Am Soc Nephrol 9:549A
32. Sanchez CP, Goodman WG, Kuizon BD, Gales B, Ettenger RB, Salusky IB (1998) Growth response to growth hormone therapy varies with bone histology in pediatric renal transplant recipients (abstract). J Am Soc Nephrol 9:550A
33. Kuizon BD, Goodman WG, Gales B, Juppner H, Salusky IB (2000) Effects of growth hormone on bone and mineral metabolism in dialyzed children (abstract). J Am Soc Nephrol 9:546A